ICE acquires Mitsubishi APIC’s Iwaki UDCA Plant

20 Oct 2021

ICE acquires Mitsubishi APIC’s Iwaki UDCA Plant

ICE Group, a global niche active pharmaceutical ingredient (“API”) and specialty ingredients company, is proud to announce its agreement on the definitive terms to acquire the Iwaki Ursodeoxycholic Acid (“UDCA”) manufacturing site from Mitsubishi API Corporation.

The Iwaki plant is a high-quality, high-purity UDCA producer, with a long heritage of stable supply to Mitsubishi Tanabe Pharma Corporation and other pharma clients worldwide. ICE’s global leadership in bile acid products and UDCA API has made the group a natural buyer and trusted partner for Mitsubishi.

Under the new ownership, and taking advantage from ICE’s vertical integration, the Japanese plant will benefit of highly efficient and effective operations that will facilitate continued and improved delivery of best-in-class UDCA API to the global customer base.

Agostino Barazza, Chief Executive Officer of ICE Group, said : “We place great value on the stringent product quality standards for UDCA API demanded by our customers. The acquisition of the Iwaki plant is a unique occasion to provide our customers with further capacity and to strengthen ICE’s position as the pre-eminent bile acids player globally”.

The transaction is expected to close in May, 2022. In the coming months, ICE will operate to build even more solid and strategic business partnerships in Japan, granting a functional continuity for customers, traditional suppliers, partners and employees.